Uric acid and incident chronic kidney disease in dyslipidemic individuals.
Uric acid and incident chronic kidney disease in dyslipidemic individuals. Curr Med Res Opin. 2017 Aug 24;:1-17 Authors: Barkas F, Elisaf M, Liberopoulos E, Kalaitzidis R, Liamis G Abstract BACKGROUND: Elevated uric acid (UA) is a recognized risk factor for chronic kidney disease (CKD). We aimed to investigate whether this association exists in dyslipidemic patients receiving multifactorial treatment. METHODS: An observational study conducted in Greece including 1,269 dyslipidemic individuals followed-up in a lipid clinic for ≥3 years. Estimated glomerular filtration rate (eGFR) was calculated by CKD-EPI equation and CKD was defined as ≤60 mL/min/1.73 m(2). We assessed the correlation between UA levels and the CKD risk after adjusting for potential confounding factors, after defining the following UA quartiles: Q1:6 mg/dL. RESULTS: After excluding patients with baseline eGFR
Bigfoot Biomedical hasn't let the coronavirus pandemic stand in the way of bringing itsÂ injection-based digitized insulin dosing platform to the U.S. market. If anything, CEO Jeffrey Brewer says the pandemic has "only crystalized the need for medical solutions like ours that facilitate remote care, remote support, and home delivery." The company has raised a total of $55 million to close its series C equity financing.Â Abbott led the round with support from existing investors, including Quadrant Capital Advisors, Senvest Capital, Janus Henderson, and Cormorant Asset Management, along with n...
CONCLUSION: SHED combined with HBO therapy was effective for treating type 2 diabetic rats. The underlying mechanism may involve SHED-mediated increase in the proliferation and trans-differentiation of islet β -cells and decrease in pro-inflammatory cytokines and apoptosis of islets.
Conclusion FIB4A is a potential marker for early detection of NBNC-HCC in patients with diabetes mellitus. However, further studies are needed to confirm these findings.
Publication date: Available online 2 June 2020Source: Diabetes &Metabolic Syndrome: Clinical Research &ReviewsAuthor(s): Amerta Ghosh, Bhavya Arora, Ritesh Gupta, Shajith Anoop, Anoop Misra
Publication date: Available online 2 June 2020Source: Diabetes &Metabolic Syndrome: Clinical Research &ReviewsAuthor(s): Timur Ekiz, Ahmet Cemal Pazarlı
Publication date: Available online 2 June 2020Source: Canadian Journal of DiabetesAuthor(s): Sheri R. Colberg
Publication date: Available online 21 March 2020Source: Canadian Journal of DiabetesAuthor(s): Chantal L. Lemieux, Margaret deGroh, Laurie Gibbons, Howard Morrison, Ying Jiang
Publication date: September–October 2020Source: Diabetes &Metabolic Syndrome: Clinical Research &Reviews, Volume 14, Issue 5Author(s): Hema S. Gopalan, Anoop Misra
Have type 1 diabetes and being forced to work during the pandemic? Here are the legal resources to know about.
Fractyl Laboratories is seeking to âturn back the clockâ in Type 2 diabetes progression with its disease-modifying therapy. FDA granted the Lexington, MA-based company IDE to launch a pivotal trial of the Revita DMR, a which holds the potential to eliminate the need for insulin injections in patients suffering from Type 2 diabetes. âInsulin is a challenging drug for patients with Type 2 diabetes because it can cause weight gain,â Harith Rajagopalan M.D. Ph.D., co-founder and CEO of Fractyl told MD+DI. âIt can cause a risk of your bloo...